Skip to main content
ALEMBIC PHARMACEUTICALS LIMITED logo

ALEMBIC PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · APLLTD ISIN · INE901L01018 LEI · 335800PM173KNG818V30 BSE.NS Manufacturing
Open in API
Filings indexed 1,367 across all filing types
Latest filing 2026-05-09 Regulatory Filings
Country IN India
Listing BSE.NS APLLTD

About ALEMBIC PHARMACEUTICALS LIMITED

https://www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited is a vertically integrated pharmaceutical organization engaged in the development, manufacturing, and marketing of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations. Established in 1907, the company operates advanced research and development centers and manufacturing facilities that adhere to international regulatory standards, including USFDA compliance. Its diverse product portfolio covers key therapeutic areas such as anti-infectives, cardiology, gynecology, gastrointestinal, and dermatology. Alembic maintains a strong global presence, supplying high-quality medications to markets in North America, Europe, and various emerging regions. The company prioritizes innovation through its focus on complex generics and specialty products, aiming to provide affordable and effective healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Please find attached herewith the Annual Secretarial Compliance Report for the F.Y. ended 31st March, 2026.
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report for the financial year ended 31st March, 2026' and is issued pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a compliance report prepared by a practicing company secretary firm, examining the listed entity's adherence to various SEBI regulations and listing obligations for the financial year ended March 31, 2026. The document includes detailed compliance status, deviations (none in this case), and management responses. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or certification only. It is a standalone compliance report focused on secretarial and regulatory compliance matters. Therefore, it fits best under the category 'Regulatory Filings (RNS)' as it is a regulatory compliance report that does not fall under other specific categories like Audit Report or Annual Report.
2026-05-09 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is an official notice from Alembic Pharmaceuticals Limited addressed to stock exchanges and shareholders. It informs about the transfer of shares with unclaimed dividends for seven consecutive years or more to the Investor Education and Protection Fund (IEPF) Demat Account, pursuant to regulatory requirements under SEBI Listing Regulations and the Companies Act. The document includes details about the procedure, deadlines, and contact information for shareholders. It is a regulatory compliance announcement related to share transfers and unclaimed dividends, not a financial report, earnings release, or management discussion. The document is about disclosure under Regulation 30 of SEBI Listing Obligations, which typically covers material events or corporate actions. Therefore, this filing best fits the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories like dividend notice or capital change.
2026-05-05 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges (BSE and NSE). It informs about the transfer of shares to the Investor Education and Protection Fund (IEPF) due to unclaimed dividends for seven consecutive years or more, pursuant to Section 124(6) of the Companies Act, 2013. The document includes a specimen notice sent to shareholders regarding this transfer. It is a regulatory announcement about a corporate action related to unclaimed dividends and share transfers, not a financial report, earnings release, or management discussion. The document is relatively short (4663 characters) and serves as an official notification to the exchanges and shareholders. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-04 English
Resignation of Director/KMP/SMP
Regulatory Filings
2026-05-04 English
Resignation of Director/KMP/SMP
Regulatory Filings
2026-05-04 English
Change in Management
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the resignation of a senior management personnel, Mr. Goldee Pardesi, from the position of Associate Vice President – Sales & Marketing. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of events or information including changes in senior management. The document includes details of the resignation and an attached resignation email from the individual. There is no financial data, report, or presentation included. The content clearly fits the category of announcements related to changes in the company's board or senior management rather than financial reports or other filings.
2026-05-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.